Valeant to buy 'female Viagra' maker Sprout Pharma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
BMO Capital Remains Bullish on Valeant Pharma (VRX) Following Announced Acquisition of 'Female Viagra' Maker Sprout Pharma
August 20, 2015 11:29 AM EDTBMO Capital reiterated an Outperform rating and $285 price target on Valeant Pharmaceuticals (NYSE: VRX) following the announced acquisition on Sprout Pharmaceuticals. Sprout recently received FDA approval for Addyi (filbanserin) , a non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD), on August 18th. Valeant will pay ~$1 billion... More
Palatin Technologies (PTN) Pops Higher; Valeant to Acquire Sprout Pharma in $1B+ Deal
August 20, 2015 7:35 AM EDTPalatin Technologies (NYSE: PTN) shares are up over 12 percent following news that Valeant Pharma (NYSE: VRX) will acquire Sprout Pharma in a $1 billion plus milestones deal. For more color on the transaction, click here.
... MorePalatin Technologies (PTN) on Watch as Rival Sprout Said Near Deal to Be Acquired
August 20, 2015 6:21 AM EDTPalatin Technologies (NYSE: PTN) is on watch amid reports from the Wall Street Journal that Valeant Pharmaceuticals (NYSE: VRX) is near a deal to by rival Sprout Pharmaceuticals, which just won FDA approval for a drug to boost a woman's libido, for $1 billion.
... More